The present invention provides a novel vaccine against mumps composed of highly immunogenic rMuVJL2 (recombinant mumps virus Jeryl Lynn2 based). Further, method to develop said immunogenic composition is described in the present invention. The vaccine according to the present invention is safe, cost effective, highly efficacious and stable and consistent in terms of productivity.